Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deucravacitinib in Alopecia Areata
NCT05556265Phase 2Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2022
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of deucravacitinib in alopecia areata, sponsored by Bristol Myers Squibb. Started Nov 2022; status: terminated.
02
Drugs
deucravacitinib
03
Conditions
alopecia areata
Beyond the preview
Go deeper on NCT05556265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05556265.